Article
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
All News
Article
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Robert B Chao, MD
Tweet
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months).
Prospective, observational study.
@RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
Richard Conway
Tweet
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Eric Dein
Tweet
#ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowing precedes erosive disease and requires more attention for early recognition. https://t.co/JLd3xVTlXM
Dr. Rachel Tate
Tweet
FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox
Mrinalini Dey
Tweet
Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk.
#RheumTwitter Abs#0540 #ACR20 @RheumNow
https://t.co/kOSToCljeq
k dao
Tweet
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
Richard Conway
Tweet
Dr McCormick reports sequential patterns of gout flare from the Boston Online Gout Study. Second attack most likely to affect ipsilateral same joint, and second most likely contralateral same joint. @rheumnow #ACR20 Abstr#672 https://t.co/2AAMvcOCk8
Dr. Rachel Tate
Tweet
CORRONA: Majority of PsA pts who initiated an advanced therapy had mild to moderate skin involvement. Decision to change therapy w/ rheumatologist based mainly on MSK symptoms. #ABS0873 #ACR20 @RheumNow https://t.co/mOXg5B7goI https://t.co/mqddMYQ3i0
Eric Dein
Tweet
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Dr. John Cush
Tweet
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast.
https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ
Dr. John Cush
Tweet
What's your ACR IQ? Test your knowledge on Day 1 of the ACR meeting and see where you place on the leaderboard. #ACR20
https://t.co/joteMBHjYl https://t.co/46Mo5n3oSq
sheila
Tweet
Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+ pts had more therapeutic benefit vs. HLA-B27- pts.
@RheumNow #ACR20 abs#0885 #ACRbest https://t.co/eD3ZGWxDkX
Richard Conway
Tweet
Dr Murdoch and colleagues report “An Apple Pie a Day Does Not Keep the Doctor Away”. An analysis of the negative depictions of gout in tv and film and how this may affect our care. @rheumnow #ACR20 Abstr#646 https://t.co/BBW0Fd5kHE
David Liew
Tweet
What is Tony Fauci's greatest achievement?
#ACR20 #LTF @RheumNow
Mrinalini Dey
Tweet
Presenting work by @drdj & I showing "Risk Factors for Lumbar Vertebral #Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip."
🗓️Session: #Epidemiology & #PublicHealth Posters II
⏰1400 GMT/ 0900 ET today!
🗒️Abs#0544
#DEXA #ACR20 @RheumNow
Meral K. El Ramahi, MD
Tweet
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
KenWarringtonMD
Tweet
Ground-breaking news... the end of #glucocorticoid use in #AAV?
very exciting to reduce GC toxicity! https://t.co/43eCofpOIX
KenWarringtonMD
Tweet
Is it Relapsing #Polychondritis or VEXAS - RP?
Data from @maferradastrong @petercgrayson tell how to tease them apart: #ACR20 #RheumTwitter https://t.co/NwfbqjX5Kw
